KR20080098022A - 인돌 유도체의 신규 시트레이트 염 및 그의 제약학적 용도 - Google Patents

인돌 유도체의 신규 시트레이트 염 및 그의 제약학적 용도 Download PDF

Info

Publication number
KR20080098022A
KR20080098022A KR1020087019047A KR20087019047A KR20080098022A KR 20080098022 A KR20080098022 A KR 20080098022A KR 1020087019047 A KR1020087019047 A KR 1020087019047A KR 20087019047 A KR20087019047 A KR 20087019047A KR 20080098022 A KR20080098022 A KR 20080098022A
Authority
KR
South Korea
Prior art keywords
disease
dementia
mammal
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087019047A
Other languages
English (en)
Korean (ko)
Inventor
안나-레나 베르그
러탠 배트
테스파이 세바투
에리카 스텔레
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20080098022A publication Critical patent/KR20080098022A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087019047A 2006-02-02 2007-01-31 인돌 유도체의 신규 시트레이트 염 및 그의 제약학적 용도 Ceased KR20080098022A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
US60/764,551 2006-02-02

Publications (1)

Publication Number Publication Date
KR20080098022A true KR20080098022A (ko) 2008-11-06

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087019047A Ceased KR20080098022A (ko) 2006-02-02 2007-01-31 인돌 유도체의 신규 시트레이트 염 및 그의 제약학적 용도

Country Status (24)

Country Link
US (2) US8008294B2 (https=)
EP (1) EP1981869A4 (https=)
JP (1) JP2009525324A (https=)
KR (1) KR20080098022A (https=)
CN (2) CN101379053A (https=)
AR (1) AR059225A1 (https=)
AU (1) AU2007210336B2 (https=)
BR (1) BRPI0706745A2 (https=)
CA (1) CA2641900A1 (https=)
EC (1) ECSP088647A (https=)
IL (1) IL192888A0 (https=)
MX (1) MX2008009719A (https=)
MY (1) MY146102A (https=)
NO (1) NO20083784L (https=)
NZ (1) NZ570849A (https=)
PE (1) PE20090192A1 (https=)
RU (1) RU2415137C2 (https=)
SA (1) SA07280004B1 (https=)
SG (1) SG169381A1 (https=)
TW (1) TW200800977A (https=)
UA (1) UA94251C2 (https=)
UY (1) UY30126A1 (https=)
WO (1) WO2007089191A1 (https=)
ZA (1) ZA200806725B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
BRPI0810216A2 (pt) * 2007-04-18 2014-10-21 Astrazeneca Ab Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar
CN101772497A (zh) * 2007-07-30 2010-07-07 阿斯利康(瑞典)有限公司 2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈柠檬酸盐的新结晶形式
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002253432B2 (en) 2001-04-05 2005-03-24 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
EP1981869A1 (en) 2008-10-22
AR059225A1 (es) 2008-03-19
SA07280004B1 (ar) 2011-10-29
ZA200806725B (en) 2009-07-29
US20070203137A1 (en) 2007-08-30
MY146102A (en) 2012-06-29
AU2007210336A1 (en) 2007-08-09
BRPI0706745A2 (pt) 2011-04-05
UA94251C2 (ru) 2011-04-26
CN101379053A (zh) 2009-03-04
US20090023732A1 (en) 2009-01-22
PE20090192A1 (es) 2009-03-20
CN101378754A (zh) 2009-03-04
WO2007089191A1 (en) 2007-08-09
UY30126A1 (es) 2007-09-28
JP2009525324A (ja) 2009-07-09
US8008294B2 (en) 2011-08-30
RU2415137C2 (ru) 2011-03-27
TW200800977A (en) 2008-01-01
EP1981869A4 (en) 2010-08-25
CA2641900A1 (en) 2007-08-09
RU2008131906A (ru) 2010-03-10
NO20083784L (no) 2008-10-13
MX2008009719A (es) 2008-09-04
AU2007210336B2 (en) 2011-03-24
SG169381A1 (en) 2011-03-30
ECSP088647A (es) 2008-08-29
NZ570849A (en) 2011-01-28
IL192888A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
KR101110457B1 (ko) Ｇｓｋ3에서 선택적 저해 효과를 갖는 신규 화합물
EP1458395B1 (en) Medical use of gsk3-inhibiting oxindole derivatives
WO2007120102A1 (en) New substituted oxindole derivatives
JP2010535200A (ja) ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
KR20090052884A (ko) Ｇｓｋ-3 억제제로서의 피리미돈 화합물
US20120101132A1 (en) New Substituted Oxindole Derivative
KR20080098022A (ko) 인돌 유도체의 신규 시트레이트 염 및 그의 제약학적 용도
EP1406883B1 (en) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3)
US20090018130A1 (en) Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid
US20120115865A1 (en) New Salts of an Indole Derivative and Their Use in Medicine
KR20080057334A (ko) 치매 및 신경변성 장애의 치료용 글리코겐 신타제 키나제억제제로서의 신규 ２-페닐-이미다조[４,５-ｂ]피리딘유도체
HK1129382A (en) New citrate salt of an indole derivative and its pharmaceutical use
HK40073574A (en) Therapeutic agent containing fused pyrimidine compound as active ingredient
HK1080856B (en) Compounds having selective inhibiting effect at gsk3

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080801

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130724

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130724

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I